Last $27.21 USD
Change Today -0.46 / -1.66%
Volume 221.0K
CMRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 5:20 PM 09/18/14 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$27.87
Previous Close
$27.67
Day High
$28.00
Day Low
$26.80
52 Week High
09/11/14 - $30.99
52 Week Low
11/7/13 - $12.96
Market Cap
970.6M
Average Volume 10 Days
682.4K
EPS TTM
$-1.35
Shares Outstanding
35.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

No Related Businessweek News Found

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

59 Employees
Last Reported Date: 08/7/14
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $275.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Chimerix, Inc. Announces Executive Appointments

Chimerix, Inc. announced the appointment of William Garrett Nichols, MD, MS as Chief Medical Officer, Essy Mozaffari, PharmD, MPH, MBA, as Vice President of Market Access and Reimbursement, and Odin Naderer, PharmD, as Vice President of Clinical Pharmacology and Translational Medicine. As Chief Medical Officer, Dr. Nichols will lead the company's clinical development and pharmacovigilance programs, initially focused on brincidofovir and expanding with additional candidate molecules in 2015. Dr. Nichols joins Chimerix from ViiV Healthcare, where he was the Head of Global Development. Dr. Mozaffari joins Chimerix from Sanofi, where he most recently served as Senior Director, Global Diabetes Market Access, Global Diabetes Commercial Operations. Dr. Naderer joins Chimerix from GlaxoSmithKline where he served most recently as Medicine Development Leader and Senior Scientific Director, Infectious Diseases.

Chimerix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 12:20 PM

Chimerix, Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-09-2014 12:20 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: M. Michelle Berrey, Chief Executive Officer, President, Chief Medical Officer and Director.

Chimerix, Inc. Announces $17.0 Million Extension of its Contract with the Biomedical Advanced Research and Development Authority

Chimerix, Inc. announced an award of $17.0 million through the extension of its contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of its broad spectrum antiviral brincidofovir (BCV, CMX001) as a medical countermeasure to treat smallpox. Chimerix received the initial award in February 2011 which supported early research and development of brincidofovir in animal models of smallpox (Contract Number HHSO100201100013C). This contract extension provides an additional $17.0 million to Chimerix for a period of 15 months, and will support Phase 3 trials expected to initiate in the second half of 2014. This contract extension with BARDA supports research and development of brincidofovir as a treatment for smallpox infections, but does not include a purchase option for the Strategic National Stockpile.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $27.21 USD -0.46

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr112.50 DKK -0.50
Bioporto A/S kr1.81 DKK -0.07
Emergent Biosolutions Inc $22.20 USD +0.03
GlaxoSmithKline PLC 1,437 GBp +2.50
Novartis AG SFr.88.45 CHF -0.45
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 238.7x
Price/Book 5.1x
Price/Cash Flow NM Not Meaningful
TEV/Sales 223.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.